







an Open Access Journal by MDPI

Tyrosine Kinase Signaling Pathways in Cancer

Guest Editor:

Prof. Dr. Adriano Angelucci

Department of Biotechnological and Applied Clinical Science, University of L'Aquila, 67100 L'Aquila, Italy

Deadline for manuscript submissions:

closed (15 September 2018)

Message from the Guest Editor

Dear Colleagues,

Protein Tyrosine Kinases (PTKs) represent the most studied topic in therapeutic oncology with several thousand of new publications per year. The interest in PTKs is due to their central role in the growth of nearly every cancer type. The early finding of BCR-ABL as effective target in curing chronic myeloid leukemia has opened a new era of the clinic oncology with the promise of non-toxic, manageable and highly specific therapies.

In this Special Issue, authors discuss the update information about PTK signaling circuits and the aberrant mechanisms associated with their oncogenic switch. Development of drugs directed against new PTK targets is also being explored. The critical evaluation of the current knowledge about PTKs is fundamental for the refinement of the current clinical therapeutic protocols and the establishment of future precision medicine.

Dr. Adriano Angelucci *Guest Editor*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us